On September 20, 2024, Novo Nordisk announced successful results from its phase 2a trial of monlunabant, showing a significant weight loss of 7.1 kg in patients after 16 weeks compared to a 0.7 kg loss with a placebo. The company plans to initiate a larger phase 2b trial in 2025 to further explore dosing and safety.